Emerging analgesic drugs for Parkinson's disease

Autores
Perez Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel Courbon, Christine; Rascol, Olivier
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition. Areas covered: Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed. Expert opinion: Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina
Fil: Rey, María Verónica. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina
Fil: Dellapina, Estelle. Université Toulouse III Paul Sabatier; Francia
Fil: Pellaprat, Jean. Université Toulouse III Paul Sabatier; Francia
Fil: Brefel Courbon, Christine. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia
Fil: Rascol, Olivier. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia
Materia
ANALGESIC TREATMENTS
BOTULINUM TOXIN
CRANIAL ELECTROTHERAPY STIMULATION
DOPAMINE AGONISTS
DULOXETINE
LEVODOPA
NON-MOTOR SYMPTOMS
OUTCOME EVALUATION
PAIN
PARKINSON'S DISEASE
PATIENT SELECTION
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
SURGICAL TREATMENTS FOR PD
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/196493
Acceder
id CONICETDig_ff69fe430ae6212d4722fb2eea579a91
oai_identifier_str oai:ri.conicet.gov.ar:11336/196493
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Emerging analgesic drugs for Parkinson's diseasePerez Lloret, SantiagoRey, María VerónicaDellapina, EstellePellaprat, JeanBrefel Courbon, ChristineRascol, OlivierANALGESIC TREATMENTSBOTULINUM TOXINCRANIAL ELECTROTHERAPY STIMULATIONDOPAMINE AGONISTSDULOXETINELEVODOPANON-MOTOR SYMPTOMSOUTCOME EVALUATIONPAINPARKINSON'S DISEASEPATIENT SELECTIONREPETITIVE TRANSCRANIAL MAGNETIC STIMULATIONSURGICAL TREATMENTS FOR PDhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition. Areas covered: Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed. Expert opinion: Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; ArgentinaFil: Rey, María Verónica. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; ArgentinaFil: Dellapina, Estelle. Université Toulouse III Paul Sabatier; FranciaFil: Pellaprat, Jean. Université Toulouse III Paul Sabatier; FranciaFil: Brefel Courbon, Christine. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; FranciaFil: Rascol, Olivier. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; FranciaInforma Healthcare2012-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/196493Perez Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel Courbon, Christine; et al.; Emerging analgesic drugs for Parkinson's disease; Informa Healthcare; Expert Opinion on Emerging Drugs; 17; 2; 6-2012; 1-151472-8214CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14728214.2012.677949info:eu-repo/semantics/altIdentifier/doi/10.1517/14728214.2012.677949info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:10:43Zoai:ri.conicet.gov.ar:11336/196493instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:10:44.034CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Emerging analgesic drugs for Parkinson's disease
title Emerging analgesic drugs for Parkinson's disease
spellingShingle Emerging analgesic drugs for Parkinson's disease
Perez Lloret, Santiago
ANALGESIC TREATMENTS
BOTULINUM TOXIN
CRANIAL ELECTROTHERAPY STIMULATION
DOPAMINE AGONISTS
DULOXETINE
LEVODOPA
NON-MOTOR SYMPTOMS
OUTCOME EVALUATION
PAIN
PARKINSON'S DISEASE
PATIENT SELECTION
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
SURGICAL TREATMENTS FOR PD
title_short Emerging analgesic drugs for Parkinson's disease
title_full Emerging analgesic drugs for Parkinson's disease
title_fullStr Emerging analgesic drugs for Parkinson's disease
title_full_unstemmed Emerging analgesic drugs for Parkinson's disease
title_sort Emerging analgesic drugs for Parkinson's disease
dc.creator.none.fl_str_mv Perez Lloret, Santiago
Rey, María Verónica
Dellapina, Estelle
Pellaprat, Jean
Brefel Courbon, Christine
Rascol, Olivier
author Perez Lloret, Santiago
author_facet Perez Lloret, Santiago
Rey, María Verónica
Dellapina, Estelle
Pellaprat, Jean
Brefel Courbon, Christine
Rascol, Olivier
author_role author
author2 Rey, María Verónica
Dellapina, Estelle
Pellaprat, Jean
Brefel Courbon, Christine
Rascol, Olivier
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv ANALGESIC TREATMENTS
BOTULINUM TOXIN
CRANIAL ELECTROTHERAPY STIMULATION
DOPAMINE AGONISTS
DULOXETINE
LEVODOPA
NON-MOTOR SYMPTOMS
OUTCOME EVALUATION
PAIN
PARKINSON'S DISEASE
PATIENT SELECTION
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
SURGICAL TREATMENTS FOR PD
topic ANALGESIC TREATMENTS
BOTULINUM TOXIN
CRANIAL ELECTROTHERAPY STIMULATION
DOPAMINE AGONISTS
DULOXETINE
LEVODOPA
NON-MOTOR SYMPTOMS
OUTCOME EVALUATION
PAIN
PARKINSON'S DISEASE
PATIENT SELECTION
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
SURGICAL TREATMENTS FOR PD
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition. Areas covered: Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed. Expert opinion: Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina
Fil: Rey, María Verónica. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina
Fil: Dellapina, Estelle. Université Toulouse III Paul Sabatier; Francia
Fil: Pellaprat, Jean. Université Toulouse III Paul Sabatier; Francia
Fil: Brefel Courbon, Christine. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia
Fil: Rascol, Olivier. Centre National de la Recherche Scientifique; Francia. Université Toulouse III Paul Sabatier; Francia
description Introduction: Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition. Areas covered: Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed. Expert opinion: Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.
publishDate 2012
dc.date.none.fl_str_mv 2012-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/196493
Perez Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel Courbon, Christine; et al.; Emerging analgesic drugs for Parkinson's disease; Informa Healthcare; Expert Opinion on Emerging Drugs; 17; 2; 6-2012; 1-15
1472-8214
CONICET Digital
CONICET
url http://hdl.handle.net/11336/196493
identifier_str_mv Perez Lloret, Santiago; Rey, María Verónica; Dellapina, Estelle; Pellaprat, Jean; Brefel Courbon, Christine; et al.; Emerging analgesic drugs for Parkinson's disease; Informa Healthcare; Expert Opinion on Emerging Drugs; 17; 2; 6-2012; 1-15
1472-8214
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14728214.2012.677949
info:eu-repo/semantics/altIdentifier/doi/10.1517/14728214.2012.677949
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781471978684416
score 12.982451

Publicaciones similares